Earnings Outlook For United Therapeutics
Portfolio Pulse from Benzinga Insights
United Therapeutics is set to announce its quarterly earnings on October 30, 2024, with analysts estimating an EPS of $6.42. The company's past performance shows mixed results, but shares have risen 56.66% over the last year. Analysts have a 'Buy' rating with a price target of $411.17, indicating a potential 17.57% upside.
October 29, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
United Therapeutics is expected to announce its quarterly earnings with an estimated EPS of $6.42. The stock has shown resilience with a 56.66% increase over the past year. Analysts maintain a 'Buy' rating with a price target of $411.17, suggesting a potential 17.57% upside.
The upcoming earnings announcement is crucial for United Therapeutics, with analysts expecting a positive EPS. The stock's strong performance over the past year and the 'Buy' rating with a significant price target upside suggest a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100